CTChen Sabrina Tan

Chen Sabrina Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chen Sabrina Tan has a total of 156 co-authors. Here are the top co-authors by number of shared publications:

  • Igor J. Koralnik

    Department of Neurology, Rush University Medical Center, Chicago, IL

    6 shared publications
  • Michelle Lifton

    Center for Virology and Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    4 shared publications
  • Stephanie Jost

    Division of Innate and Comparative Immunology, Center for Human Systems Immunology, Department of Surgery, Duke University School of Medicine , Durham, North Carolina , USA

    4 shared publications
  • Francisco M. Marty

    Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts

    3 shared publications
  • Jenny Ahn

    Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center , Boston, Massachusetts

    3 shared publications
  • Kyle Kroll

    Division of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA

    3 shared publications

Latest Publications

  • Open Access

    IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients

    by Chen Sabrina Tan, Shweta Anjan, Ella J Ariza-Heredia, Francisco Magana, Timothy D Minniear, Dipleen Kaur, Yngve Falck-Ytter, Lindsey Baden

    Immunocompromised individuals experience disproportionately severe outcomes from respiratory syncytial virus (RSV) infection, yet direct evidence to guide vaccination in this population remains limited. To support clinical and shared decision-making for the 2025–2026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened a multidisciplinary expert panel to develop rapid, evidence-based recommendations on RSV vaccination among immunocompromised adults and children. The panel conducted a systematic review of comparative effectiveness and harms data published between August 2024 and July 2025, supplemented by additional evidence from the Vaccine Integrity Project. Certainty of evidence and recommendation strength were assessed using the GRADE approach. Two test-negative case–control studies in immunocompromised adults showed vaccination reduced RSV-associated hospitalization by 70% (95% CI: 66%–73%). Indirect evidence from older-adult populations demonstrated 81% effectiveness (95% CI: 52%–92%) against critical illness. Across three randomized trials, serious adverse events were comparable between vaccinated and unvaccinated groups. Guillain–Barré syndrome was rare, with an estimated 11 excess cases per million doses. Given substantial reduction in severe disease and low likelihood of serious harm, the panel issued a strong recommendation for age-appropriate RSV vaccination in adults and adolescents with compromised immunity. For immunocompromised patients <18 years, shared decision-making is advised. Timing should be individualized by subgroups, considering treatment cycles, transplant status, and B-cell–depleting therapies. Household members should remain up to date when eligible, and coadministration with influenza and coronavirus disease 2019 vaccines is acceptable. Research priorities include correlates of protection, durability of immunity, subgroup safety, and the role of booster doses.


  • Open Access

    Anti-IL-15 treatment reduces acute lentivirus inflammation and signaling in the brain

    by Daniel R. Ram, Raja Mohan Gopalakrishnan, Malika Aid, Kyle Kroll, Jasmine Miftahof, Omar Aristizabal, Eunice Kayitare Gikundiro, Caitlin Davis, Marco M. Hefti, Kimberly L. Fiock, et al.


  • Open Access

    Ebola’s hidden front: Neurological involvement and pathogenesis

    by Blake Bernauer, Jack Siemering, Chen Sabrina Tan


  • Open Access

    Neurological Manifestations of SARS-CoV-2

    by Jasmine Miftahof, Blake Bernauer, Chen Sabrina Tan

    Neurocognitive symptoms have emerged as notable sequelae of SARS-CoV-2 infection (COVID-19). Although primarily a respiratory virus, SARS-CoV-2 has been associated with central nervous system (CNS) changes observed in both clinical and experimental settings. To better understand these effects and their pathological mechanisms, we conducted a systematic literature search of published studies and employed a qualitative, analytical approach to identify and synthesize key findings from peer-reviewed studies, including large-scale retrospective clinical cohorts, human autopsy reports, animal models (murine, non-human primate), and in vitro brain organoid systems. While viral components were detected in post mortem central nervous system tissues, COVID-19 neuropathology appears to stem primarily from immune-mediated inflammation and vascular injury rather than direct CNS infection. Persistent glial activation and BBB disruption may underlie the long-term neurological symptoms reported in long COVID-19. Although animal models offer mechanistic insight, species-specific differences necessitate cautious extrapolation to human pathology. Further investigation into the chronic effects of SARS-CoV-2 on the brain is essential to guide long-term clinical management and therapeutic development.


  • Immune Responses to BK Virus in Renal Transplant Recipients Receiving Intravenous Immunoglobulin Treatment

    by Kevin D He, Simon B Gressens, Darshana M Dadhania, Hannah M Gilligan, Caitlin Davis, Emmanuel Edusei, Jenny Ahn, Michelle Lifton, Diana V Pastrana, Steven Kleiboeker, et al.

    Background: BK polyomavirus (BKPyV) DNAemia in renal transplant recipients increases risk of allograft failure, but BKPyV-specific therapies are not available. While treatment with intravenous immunoglobulin (IVIG) has been reported, safety in a prospective randomized controlled setting is uncertain, and host immune response to BKPyV after IVIG is not well characterized. Methods: We investigated host immune responses to BKPyV in a multicenter, prospective, randomized, double-blinded, placebo-controlled pilot study of IVIG with protocolized immunosuppression reduction in adult kidney transplant recipients with BK DNAemia. Participants received 2 infusions of 1 g/kg up to 70 g each, 1 month apart, of IVIG or placebo and were followed for 1 year with adverse event monitoring. The primary endpoint was safety and tolerability of IVIG. Neutralizing antibody (nAb) to common BKPyV strains and BK-specific CD4+/CD8+ T-cell and natural killer cell responses were evaluated. Results: There were no adverse events. Forty percent of recipients in the treatment arm and 44.4% in the control arm cleared BK DNAemia at 3 months (relative risk, 0.90 [95% confidence interval, .23–2.89]). Overall, 80% of recipients with a sequenced BK genotype possessed cognate nAbs at baseline, and 100% acquired them by 3 months. Viral clearance was associated with higher percentages of BKPyV-specific CD8+ T cells prior to IVIG treatment (0.19% vs 3.01%; P < .01). Conclusions: In this pilot study, treatment with 2 doses of IVIG was safe, but its impact on viral clearance is unclear. Control of DNAemia may depend upon intrinsic virus-specific host cellular and humoral response, but further studies are needed. Clinical Trials Registration: NCT02659891.


  • Neuroborreliosis

    by Kevin D. He, Hawra Al Lawati, Nurhan Torun, C. Sabrina Tan

    Background: Neuroborreliosis is involvement of the nervous system in Lyme disease and can often be overlooked as a diagnosis in patients presenting with cranial neuropathies and meningitis in an endemic area. There can be variability in presentation with respect to the involved cranial nerves, making the diagnosis challenging. To the best of our knowledge, there have been no reported cases of Lyme disease cranial neuropathy occurring with simultaneous periorbital skin and soft tissue inflammation in the literature. Case: We present the case of a healthy 25-year-old man who presented to the emergency department with headache, diplopia, and left eye pain after experiencing fever, malaise, and a recent history of unilateral facial palsy that improved a few weeks prior. He lived in a Lyme disease endemic area and often encountered ticks. He was found to have an abduction deficit in his left eye, preseptal and postseptal orbital inflammation with bilateral optic perineuritis, and a lymphocytic pleocytosis in the cerebrospinal fluid accompanied by an elevated antibody index, consistent with a diagnosis of Lyme neuroborreliosis. He was treated with doxycycline and empiric bacterial coverage, with symptom resolution at follow-up. Conclusion: This case represents an unusual combination of cranial neuropathies and is the first report of orbital inflammation driven by Lyme neuroborreliosis, thought to be caused by contiguous spread of inflammation from affected portions of the nervous system. Although neuroborreliosis is less commonly encountered in the United States than in Europe, providers should maintain a high index of suspicion for this entity when patients present with multiple cranial neuropathies in an endemic area and not exclude Lyme disease on the basis of skin and soft tissue inflammation.

  • Open Access

    Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

    by Boris Julg, Kathryn E. Stephenson, Frank Tomaka, Stephen R. Walsh, C. Sabrina Tan, Ludo Lavreys, Michal Sarnecki, Jessica L. Ansel, Diane G. Kanjilal, Kate Jaegle, et al.

    Mosaic HIV-1 vaccines have been shown to elicit robust humoral and cellular immune responses in people living with HIV-1 (PLWH), that had started antiretroviral therapy (ART) during acute infection. We evaluated the safety and immunogenicity of 2 mosaic vaccine regimens in virologically suppressed individuals that had initiated ART during the chronic phase of infection, exemplifying the majority of PLWH. In this double-blind, placebo-controlled phase 1 trial (IPCAVD013/HTX1002) 25 ART-suppressed PLWH were randomized to receive Ad26.Mos4.HIV/MVA-Mosaic (Ad26/MVA) (n = 10) or Ad26.Mos4.HIV/Ad26.Mos4.HIV plus adjuvanted gp140 protein (Ad26/Ad26+gp140) (n = 9) or placebo (n = 6). Primary endpoints included safety and tolerability and secondary endpoints included HIV-specific binding and neutralizing antibody titers and HIV-specific T cell responses. Both vaccine regimens were well tolerated with pain/tenderness at the injection site and fatigue, myalgia/chills and headache as the most commonly reported solicited local and grade 3 systemic adverse events, respectively. In the Ad26/Ad26+gp140 group, Env-specific IFN-γ T cell responses showed a median 12-fold increase while responses to Gag and Pol increased 1.8 and 2.4-fold, respectively. The breadth of T cell responses to individual peptide subpools increased from 11.0 pre-vaccination to 26.0 in the Ad26/Ad26+gp140 group and from 10.0 to 14.5 in the Ad26/MVA group. Ad26/Ad26+gp140 vaccination increased binding antibody titers against vaccine-matched clade C Env 5.5-fold as well as augmented neutralizing antibody titers against Clade C pseudovirus by 7.2-fold. Both vaccine regimens were immunogenic, while the addition of the protein boost resulted in additional T cell and augmented binding and neutralizing antibody titers. These data suggest that the Ad26/Ad26+gp140 regimen should be tested further.


  • Upregulation of the NKG2D Ligand ULBP2 by JC Polyomavirus Infection Promotes Immune Recognition by Natural Killer Cells

    by Stephanie Jost, Jenny Ahn, Sarah Chen, Taylor Yoder, Kayitare Eunice Gikundiro, Esther Lee, Simon B Gressens, Kyle Kroll, Melissa Craemer, G Campbell Kaynor, et al.

    Background: JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a potentially fatal complication of severe immune suppression with no effective treatment. Natural killer (NK) cells play critical roles in defense against viral infections; however, NK-cell response to JCPyV infection remains unexplored. Methods: NK- and T-cell responses against the JCPyV VP1 were compared using intracellular cytokine staining upon stimulation with peptide pools. A novel flow cytometry-based assay was developed to determine NK-cell killing efficiency of JCPyV-infected astrocyte-derived SVG-A cells. Blocking antibodies were used to evaluate the contribution of NK-cell receptors in immune recognition of JCPyV-infected cells. Results: In about 40% of healthy donors, we detected robust CD107a upregulation and IFN-γ production by NK cells, extending beyond T-cell responses. Next, using the NK-cell–mediated killing assay, we showed that coculture of NK cells and JCPyV-infected SVG-A cells leads to a 60% reduction in infection, on average. JCPyV-infected cells had enhanced expression of ULBP2—a ligand for the activating NK-cell receptor NKG2D, and addition of NKG2D blocking antibodies decreased NK-cell degranulation. Conclusions: NKG2D-mediated activation of NK cells plays a key role in controlling JCPyV replication and may be a promising immunotherapeutic target to boost NK-cell anti-JCPyV activity.


  • Open Access

    Upregulation of the NKG2D ligand ULBP2 by JC polyomavirus infection promotes immune recognition by natural killer cells

    by Stephanie Jost, Jenny Ahn, Sarah Chen, Taylor Yoder, Kayitare Eunice Gikundiro, Esther Lee, Simon B. Gressens, Kyle Kroll, Melissa Craemer, G. Campbell Kaynor, et al.

    JC polyomavirus (JCPyV) establishes a chronic infection in 70-90% of the world’s population. In immunocompetent individuals, JCPyV chronic infection is asymptomatic and not associated with diseases. However, JCPyV causes progressive multifocal leukoencephalopathy (PML), a potentially fatal complication of severe immune suppression due to monoclonal antibody treatments for cancer, autoimmune diseases and transplantation, or due to uncontrolled HIV infection. There is currently no effective treatment against PML and novel immunotherapies are urgently needed to decrease the morbidity and mortality caused by JCPyV. The risk of developing PML increases with loss of immune control by JCPyV-specific T cells and antibodies. Natural killer (NK) cells play critical roles in defense against viral infections, yet NK cell contribution to the control of JCPyV infection remains largely unexplored. Here, we first compared NK and T cell responses against JCPyV VP1 peptide pools. In about 40% of healthy donors, we detected robust CD107a upregulation and IFN-γ production by NK cells, extending beyond T cell responses. Next, using a novel flow cytometry-based killing assay, we showed that co-culture of NK cells and JCPyV-infected astrocyte-derived SVG-A cells leads to a 60% reduction in infection, on average. Expression of ligands for the activating NK cell receptor NKG2D was modulated in JCPyV-infected cells, with overall enhanced expression of ULBP2. To evaluate the impact of NKG2D triggering on NK cell-mediated elimination of JCPyV-infected cells, we performed co-cultures in the presence of NKG2D blocking antibodies, which resulted in decreased NK cell degranulation. Altogether, these findings suggest NKG2D-mediated activation may play a key role in controlling JCPyV replication and may be a promising immunotherapeutic target to boost NK cell anti-JCPyV activity. Author Summary: The human polyomavirus JC (JCPyV) infects most people for life but only causes disease in persons with a compromised immune system. In particular, JCPyV reactivation in the brain is responsible for the development of progressive multifocal leukoencephalopathy (PML). There is currently no effective treatment for PML, which is often fatal. Natural killer (NK) cells are effector cells of the innate immune system that play critical roles in defense against viral infections, yet their contribution to the control of JCPyV infection remains largely unexplored. The current study shows that NK cells can eliminate cells infected with JCPyV and that immune recognition is partly mediated by NKG2D, an activating ligand expressed on NK cells, and its binding to ULBP2, a stress-induced ligand expressed on infected cells. Our findings provide new insights into immune mechanisms involved in JCPyV immunity, and unveil opportunities to harness NK cell function in future therapeutic strategies to target JCPyV.

  • Open Access

    Increased IL-6 expression precedes reliable viral detection in the rhesus macaque brain during acute SIV infection

    by Raja Mohan Gopalakrishnan, Malika Aid, Noe B. Mercado, Caitlin Davis, Shaily Malik, Emma Geiger, Valerie Varner, Rhianna Jones, Steven E. Bosinger, Cesar Piedra-Mora, et al.

    Knowledge of immune activation in the brain during acute HIV infection is crucial for the prevention and treatment of HIV-associated neurological disorders. We determined regional brain (basal ganglia, thalamus, and frontal cortex) immune and virological profiles at 7 and 14 days post infection (dpi) with SIV mac239 in rhesus macaques. The basal ganglia and thalamus had detectable viruses earlier (7 dpi) than the frontal cortex (14 dpi) and contained higher quantities of viruses than the latter. Increased immune activation of astrocytes and significant infiltration of macrophages in the thalamus at 14 dpi coincided with elevated plasma viral load, and SIV colocalized only within macrophages. RNA signatures of proinflammatory responses, including IL-6, were detected at 7 dpi in microglia and interestingly, preceded reliable detection of virus in tissues and were maintained in the chronically infected macaques. Countering the proinflammatory response, the antiinflammatory response was not detected until increased TGF- β expression was found in perivascular macrophages at 14 dpi. But this response was not detected in chronic infection. Our data provide evidence that the interplay of acute proinflammatory and antiinflammatory responses in the brain likely contributed to the overt neuroinflammation, where the immune activation preceded reliable viral detection.